Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KMT2A rearrange FLT3 exon 14 ins |
| Therapy | FHD-286 + Quizartinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KMT2A rearrange FLT3 exon 14 ins | acute myeloid leukemia | sensitive | FHD-286 + Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, FHD-286 and Vanflyta (quizartinib) synergistically inhibited viability in acute myeloid leukemia cells harboring KMT2A rearrangements and FLT3-ITD in culture (PMID: 40089460). | 40089460 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40089460) | Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. | Full reference... |